News
NVAX
12.75
+15.80%
1.74
Novavax (NVAX) Could Be 82% Overvalued On Plague Headlines And Pfizer Deal Focus
Simply Wall St · 1d ago
Novavax Inc. Stock Rises 15.8%, Outperforms Peers
Dow Jones · 2d ago
A New War on Cancer? NIH's Vaccine Initiative Sparks Biotech Stock Rally
Benzinga · 2d ago
NIH makes big bet on public-private partnership over cancer vaccines, NYT says
TipRanks · 2d ago
Reported Earlier: 'Cancer Vaccines Are the N.I.H's Next Big Bet' - The New York Times
Benzinga · 2d ago
Humana, Evolution Metals & Technologies, Fastly And Other Big Stocks Moving Higher On Friday
Benzinga · 2d ago
Novavax price target raised to $8 from $7 at BofA
TipRanks · 2d ago
Novavax, Inc. (NVAX) is Attracting Investor Attention: Here is What You Should Know
NASDAQ · 2d ago
Novavax: Sell The False Plague Breakout
Seeking Alpha · 3d ago
Novavax: Vaccine Maker Sees Momentum In 2026, But Growth Story Holds Fundamental Risks
Seeking Alpha · 3d ago
Should Updated COVID Vaccine Approvals Require Action From Novavax Stock Investors?
Simply Wall St · 3d ago
'Russia Denies Report of Second Case of Illness in Siberia' - Bloomberg
Benzinga · 4d ago
Transcript: Novavax Q2 2026 Earnings Conference Call
Benzinga · 4d ago
Pandemic Panic Is Back on Wall Street. What to Know About the Russian Plague Scare.
Barron‘s · 5d ago
Novavax Inc. Stock Slides 9.9%, Underperforms Peers
Dow Jones · 5d ago
Notable Tuesday Option Activity: AWR, NVAX, INTC
NASDAQ · 5d ago
Novavax Stock (NVAX) Plunges After WHO Calms Plague Fears
TipRanks · 5d ago
Novavax Stock Falls Back: What's Going On?
Benzinga · 5d ago
Unusually active option classes on open October 6th
TipRanks · 5d ago
Novavax, Moderna cool as WHO downplays plague-related death in Russia
Seeking Alpha · 5d ago
More
Webull provides a variety of real-time NVAX stock news. You can receive the latest news about Novavax Inc through multiple platforms. This information may help you make smarter investment decisions.
About NVAX
Novavax, Inc. is a biotechnology company. It is focused on addressing global health challenges through its vaccines and its proven technology platform, including protein-based nanoparticles and its Matrix-M adjuvant. Matrix-M can be used to create vaccines for a variety of diseases to help tackle some of the pressing health challenges. Its proprietary Matrix-M adjuvant, when added to vaccines, has been shown to help induce a stronger and longer-lasting immune response. Its recombinant protein-based nanoparticle technology has been shown to be highly immunogenetic. Its technology platform is used in its authorized COVID-19 vaccine and the R21/Matrix-M adjuvant malaria vaccine. Its late-stage programs include a COVID-19-Influenzavaccine candidate, and an influenza vaccine candidate. R21/Matrix-M adjuvant malaria vaccine, a malaria vaccine developed by its partner. It provides Matrix-M adjuvant for use in various programs in preclinical and clinical stage, and preclinical investigations.